Crunch Network

More Startup Funding Is Available, But Who’s Getting It?

Next Story

The Startup Illusion

Last year was fantastic for startup fundraising, continuing an upward trend with a dramatic increase to more than $47 billion (a 62 percent increase from 2013’s figures). On the surface, this is great news — more venture capitalists are pouring more money into startups, thereby increasing the amount of available resources for new ideas.

But the type of companies receiving this funding, and the way this funding is distributed, illustrate a system that prefers certain industries and certain types of ideas over others. Popular consumer apps get all the attention, but the number of these ideas that actually get investments is relatively low. The elite app ideas will always get tremendous financial backing, but other, less-flashy industries with more environmental conditions that favor success are starting to emerge as worthy entrepreneurial ventures.

How Is The Money Distributed?

The trends dictating this increase in total available funding are actually complicating the nature of its availability. While more total money is being invested in startups, that capital is being lumped into larger sums over the course of fewer total rounds of funding.

To substantiate this, consider the fact that the median value of a round of Series D funding spiked roughly 80 percent, from $16.1 million to $29 million in 2013 and 2014, respectively. Series A, B and C funding also saw similar increases, though Series D was the most notable of the group.

Popular consumer apps get all the attention, but the number of these ideas that actually get investments is relatively low.

Anecdotally, you can also see this pattern in major tech startups over the past few years. For example, transportation app giant Uber raised two rounds of funding, each of which constituted more than a billion dollars.

Uber competitor Lyft held its own with a $250 million round, and Airbnb managed to earn a $475 million round of investment. Investors are hungry for “sure thing” ideas in consumer tech, but these aren’t the only types of businesses getting these giant sums of capital.

Trends In Mobile, Biotech, And Pharmaceuticals

The type of investments sought by venture capitalists are also evolving. Some trends are obvious and predictable. For example, startups focusing on mobile technologies hit a new record in 2014, attracting $7.8 billion (a 109 percent increase over the previous year). Companies like Uber get the most attention because they are consumer-facing and highly practical to a wide audience.

Biotechnology companies, too, are attracting bigger chunks of the national pool of investment capital. While the biotech industry has seen its ups and downs over the course of the past decade, there are a handful of trends making it easier for biotech companies to emerge and get funding.

New regulations and laws are making it easier for biotech companies to find a foundation. For example, the Innovation Act is reducing costly, frivolous lawsuits against biotech firms, and the Affordable Care Act (ACA) is introducing millions of new patients into the healthcare system, increasing demand.

Pharmaceutical companies are also receiving larger sums of this greater-available venture capital. Because new drugs and medicines take an enormous amount of time to research, develop and test, they need more funding than ever — but you rarely hear about these companies unless you work in the industry, because they aren’t consumer-friendly or immediately practical until they’re ready to be released to the market.

Pharmaceuticals aren’t sexy, but they can attract tons of potential venture capital by doing one thing — proving their effectiveness. Early trials and preliminary research that suggests a sure bet attracts investors much in the same way that consumer tech companies with an existing customer base attract them.

Finally, because biotech companies and pharmaceutical companies are enjoying a mutually beneficial landscape for development and capital acquisition, more partnerships between these types of companies are forming. Entrepreneurs have more possibilities before them, more exit strategies and broader access to additional resources — which makes them far more attractive to potential investors looking for safe ways to build wealth.

The Takeaways For Aspiring Entrepreneurs

The inflated numbers of public deals like Uber’s funding have filled hopeful entrepreneurs with dreams of striking it big with one great idea — a modern, more professional kind of “get rich quick scheme.” The release of statistics and trends related to funding increasing over the past several years have done their part to attract even more new entrepreneurs to business development. In effect, we have a national culture of entrepreneurship that treats tech leaders like rock stars, but the reality is quite different.

The tiny percentage of consumer-facing startups with a high propensity for global success have a certain allure, but the high failure rate and inconsistently lumped funding makes them inadvisable for most entrepreneurs to pursue. Biotech and pharmaceutical companies, however, are seeing a boon in both funding and environmental conditions that favor success.

If you can find an idea with grounding in real research, take advantage of the new regulations and healthcare institutions available, and partner with similar or complementary emerging firms. You’ll have a much better chance at landing those capital investments and leading a business to success.

Featured Image: smutny pan/Shutterstock